{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator%3A+Atomoxetine%2C+Placebo",
    "query": {
      "intervention": "Active Comparator: Atomoxetine, Placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T12:35:48.099Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01343628",
      "title": "A Gene by Medication Interaction to the Acute Effects of Alcohol",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol-induced Cue-craving",
        "Alcohol Sensitivity"
      ],
      "interventions": [
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        },
        {
          "name": "Active Comparator: Atomoxetine, Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 43,
      "start_date": "2008-01",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2012-05-31",
      "last_synced_at": "2026-09-29T12:35:48.099Z",
      "location_count": 1,
      "location_summary": "Charlottesville/ Richmond, Virginia",
      "locations": [
        {
          "city": "Charlottesville/ Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01343628"
    },
    {
      "nct_id": "NCT07577661",
      "title": "Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Obstructive Sleep Apnea",
        "Sleep-disordered Breathing"
      ],
      "interventions": [
        {
          "name": "Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy)",
          "type": "OTHER"
        },
        {
          "name": "Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition",
          "type": "DEVICE"
        },
        {
          "name": "Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition",
          "type": "DRUG"
        },
        {
          "name": "Placebo; placebo comparator condition",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-09-01",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-29T12:35:48.099Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07577661"
    },
    {
      "nct_id": "NCT00716274",
      "title": "Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder",
        "Dyslexia"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "10 Years to 16 Years"
      },
      "enrollment_count": 110,
      "start_date": "2008-09",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-09-29T12:35:48.099Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00716274"
    },
    {
      "nct_id": "NCT04085172",
      "title": "A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Guanfacine hydrochloride (TAK-503)",
          "type": "DRUG"
        },
        {
          "name": "Atomoxetine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 396,
      "start_date": "2019-09-18",
      "completion_date": "2025-09-02",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-29T12:35:48.099Z",
      "location_count": 20,
      "location_summary": "Dothan, Alabama • Anaheim, California • Imperial, California + 17 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04085172"
    },
    {
      "nct_id": "NCT01244490",
      "title": "Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Extended-release Guanfacine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Atomoxetine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 338,
      "start_date": "2011-01-17",
      "completion_date": "2013-05-01",
      "has_results": true,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-09-29T12:35:48.099Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Maitland, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Rochester Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01244490"
    }
  ]
}